The U.S. in vitro diagnostics market size accounted for USD 34.98 billion in 2024, grew to USD 35.43 billion in 2025 and is projected to surpass around USD 42.63 billion by 2034, growing at a CAGR of 2% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. In Vitro Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. In Vitro Diagnostics Market Revenue and Volume, by Product, 2024-2034
8.1.1. Reagents
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Instruments
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Services
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. U.S. In Vitro Diagnostics Market Revenue and Volume, by Test Location, 2024-2034
9.1.1. Point of Care
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Home Care
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. U.S. In Vitro Diagnostics Market Revenue and Volume, by Technology, 2024-2034
10.1.1. Immunoassay
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Hematology
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Clinical Chemistry
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Molecular Diagnostics
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1.5. Coagulation
10.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1.6. Microbiology
10.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1.7. Others
10.1.7.1. Market Revenue and Volume Forecast (2021-2034)
11.1. U.S. In Vitro Diagnostics Market Revenue and Volume, by Application, 2024-2034
11.1.1. Diabetes
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Cardiology
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Nephrology
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1.4. Infectious Disease
11.1.4.1. Market Revenue and Volume Forecast (2021-2034)
11.1.5. Oncology
11.1.5.1. Market Revenue and Volume Forecast (2021-2034)
11.1.6. Drug Testing
11.1.6.1. Market Revenue and Volume Forecast (2021-2034)
11.1.7. Autoimmune Diseases
11.1.7.1. Market Revenue and Volume Forecast (2021-2034)
11.1.8. Others
11.1.8.1. Market Revenue and Volume Forecast (2021-2034)
12.1. U.S. In Vitro Diagnostics Market Revenue and Volume, by End User, 2024-2034
12.1.1. Standalone Laboratories
12.1.1.1. Market Revenue and Volume Forecast (2021-2034)
12.1.2. Hospitals
12.1.2.1. Market Revenue and Volume Forecast (2021-2034)
12.1.3. Academic & Medical Schools
12.1.3.1. Market Revenue and Volume Forecast (2021-2034)
12.1.4. Point-of-Care
12.1.4.1. Market Revenue and Volume Forecast (2021-2034)
12.1.5. Others
12.1.5.1. Market Revenue and Volume Forecast (2021-2034)
13.1. U.S.
13.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)
13.1.2. Market Revenue and Volume Forecast, by Test Location (2021-2034)
13.1.3. Market Revenue and Volume Forecast, by Technology (2021-2034)
13.1.4. Market Revenue and Volume Forecast, by Application (2021-2034)
13.1.5. Market Revenue and Volume Forecast, by End User (2021-2034)
14.1. Alere, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Beckman Coulter
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. BD
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Bio-Rad laboratories
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Danaher
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbott Laboratories
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Thermo Fisher Scientific Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. bioMérieux, Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Quest Diagnostics
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Illumina, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample